Search results
Merck to buy eye-focused drug developer EyeBio for as much as $3 billion By Reuters
Investing.com· 6 days agoMerck said in February it was in the market for deals of up to $15 billion, and has already struck...
CNBC Daily Open: Dow drops on weak manufacturing data, GameStop soars
CNBC· 21 hours agoTraders work as a screen displays the trading information for GameStop and AMC Theatres on the floor...
Merck nears $1.3 billion cash deal for eye-drug company EyeBio, WSJ reports
Reuters via Yahoo Finance· 7 days agoMerck has said it's in the market for deals of up to around $15 billion as it plans ways to deal...
Summit Therapeutics cancer therapy succeeds in late-stage China study
WHTC 1450 Holland· 5 days ago(Reuters) - Summit Therapeutics said on Thursday its experimental therapy to treat patients with a type of lung cancer met the main goal of a late-stage study conducted in China. The company ...
Lack of insurance keeps many Americans from best cancer meds
Medical Xpress· 1 day agoThe study was led by ACS researcher Dr. Jingxuan Zhao. ICIs include such blockbuster cancer...
Merck Nears $1.3 Billion Cash Deal for Eye-Drug Company EyeBio, WSJ Reports
US News & World Report· 7 days agoMerck did not immediately respond to Reuters' request for a comment, while Eyebiotech declined to comment. Eyebiotech is a clinical stage opthalmology company, with operations in the U.S. and ...
Merck to pay as much as $3 billion for eye treatment startup
Crain's New York Business· 6 days agoWhile it raised its profit and sales forecast for the year on Keytruda sales, Merck has been on the...
TuHURA reports breakthrough in cancer vaccine trial By Investing.com
Investing.com· 1 day agoTuHURA Biosciences, Inc., in collaboration with Kintara Therapeutics, Inc. (NASDAQ:KTRA), has...
Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response...
Benzinga· 4 days agoMDNA11 demonstrates durable response in pancreatic cancer patient with 100% regression of target and non-target lesions for over 104 weeks and continues to show remission 4 months after stopping treatment Melanoma
ASCO24: Tagrisso in the spotlight, Caribou’s adjustment and Lilly’s KRAS competitor
BioPharma Dive via Yahoo Finance· 1 day agoOnly 1% of those participants discontinued treatment due to side effects, Lilly said. The company...